🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 760.38 -0.5% NASDAQ 100: 705.16 +0.1% Dow Jones: 534.08 -0.5%

Fieldview Capital Management - Q2 2026 13F Filings

FI

Fieldview Capital Management, LLC

CIK: 0002040221
Address: Michigan Niles 2003 Morris Drive
$350.71 M
Portfolio Value
507
Assets Held
Reporting Period: Q2 2026
Filing Status:
Active
Last Updated: 08/14/2026

Portfolio Summary (Q2 2026)

View Full Portfolio Analysis

Top Buys

Q2 2026
1. MAT Mattel
+$4.71 M
2. BKNG Booking Holdings
+$4.55 M
3. SGI Somnigroup International
+$4.49 M
4. KTB Kontoor Brands
+$3.78 M
5. EXPE Expedia Group
+$3.08 M

Top Sells

Q2 2026
1. BIIB Biogen
−$3.55 M
2. WSBC Wesbanco
−$3.45 M
3. TER Teradyne
−$3.16 M
4. BNL Broadstone Net Lease
−$2.8 M
5. NHI National Health Investors
−$2.75 M

Asset Allocation

Stocks/ETFs
+2.37%
$350.71 M 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Fieldview Capital Management Q2 2026 Filing Summary

Fieldview Capital Management, LLC filed its 13F report for Q2 2026 on August 14, 2026. The portfolio totaled 350.71 M reflecting a +2.37% change from the prior quarter, spanning 507 assets. The top 10 holdings comprised 11.7% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 280 new positions and 241 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Fieldview Capital Management’s Q2 2026 Filing

Fieldview Capital Management submitted their Form 13F-HR for the Q2 2026 period on 08/14/2026. This was the only submission for the quarter.

In the Q2 2026 filing, Fieldview Capital Management reported a managed portfolio value of 350.71 M, consisting of 507 individual positions.

This page displays the raw filing documents. To see which stocks Fieldview Capital Management bought or sold during Q2 2026, please visit Fieldview Capital Management's Portfolio Analysis page.